- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03260803
Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women
Valuating the Effects of Oligopin Supplementation on the Turnover of Bone Formation and Antioxidant Changes in Postmenopausal Osteopenic Women: A Randomized Double-blind Clinical Trial With Placebo-concurrent Controls
Osteoporosis fractures impose a significant economic burden on the health system. There is evidence that osteoporosis has a high prevalence in Iran (4.8% for men and 7.7% for women), and the frequency of osteopenia is 36.8% for men and 39.3% for women in Iran Accordingly, the prevention of osteopenia progression towards osteoporosis has been considered as an important issue in medicine. Bone is a dynamic tissue that is constantly being remodeled thus the equilibrium between bone formation and resorption done by simultaneously regulating osteoclasts and osteoblasts is important. Imbalance between bone deposition and resorption contributes to reducing bone mineral density and hence increasing the risk of osteoporosis
Recently, new therapies have been focused on use of medicinal herbs, especially phytochemicals. Among phytochemicals, phytonutrients, and especially polyphenols, can act both on osteoblast and on osteoclast.
Pine bark extract (oligopin) is a rich source of polyphenols that exerts strong antioxidant and anti-inflammatory activities. It has also beneficial effects on bone turnover based on in vitro studies and animal models. Investigators aimed to investigate the effects of oligopin on bone turnover markers and plasma and peripheral mononuclear cells oxidative stress in postmenopausal women with osteopenia in a double-blind randomized clinical trial. Participants are forty four women with osteopenia divided into two groups randomly (22, having oligopin, 150 mg, once daily, for 12 weeks). The 2nd group (22 women with osteopenia) receives the same amount of the placebo. At the first and the end of the study, blood sample are taken to measure in order to peripheral blood mononuclear cells isolation and plasma separation. The levels of bone alkaline phosphatase and carboxy terminal collagen type I in plasma oxidative stress markers such as total anti-oxidant capacity, malondialdehyde, and protein carbonyl were evaluated. Furthermore, oxidative stress will be evaluated in peripheral blood mononuclear cells by measurement of expression and activity of magnesium superoxide dismutase,catalase and Nuclear factor (erythroid-derived 2)-like 2.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 0098
- Tehran University Of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inclusion criteria: Postmenopausal women; Aged between 50-65; Diagnosis of osteopenia based on Tscore ( -2.5 SD ≤ Tscore ≤ -1 SD); To have equal physical, pediatric and complementary therapies for at least three months before entrance to study ;Absence of history of Bone Diseases; Absence of the history of chronic diseases including cancer, diabetes, kidney failure, liver disease, systemic inflammatory diseases, degenerative joint diseases and rheumatologic disorders, primary thalassemia, hyperparathyroidism, hyperthyroidism-Cushing's, Hypercalcaemia syndrome, Hyperglycemia ;Absence of gastrointestinal disease including Crohn's disease, ulcerative colitis, celiac disease, and chronic diarrhea and gastric or duodenal ulcers treated or with a history of gastrointestinal bleeding (according to the patient's history); Absence of history of the use of drugs that affect bone metabolism and have been regularly used for at least 6 months in the past two years: such as osteoporosis drugs (bisphosphonates, estrogen receptor selective agonists / selective antagonists, alternative HRTs, PTH), diuretics, thiazides, anticonvulsants (phenytoin, phenobarbital, sodium valproate), glucocorticoids, nonsteroidal anti-inflammatory drugs such as analgesics (nonsteroidal anti-inflammatory drugs such as naproxen, aspirin and ibuprofen), cigarettes; Absence of motor disabilities, skeletal disorders, untreated psychiatric illnesses such as psychosis, Alzheimer's disease, Parkinson's disease; To accept randomization; Absence of morbid Obesity: BMI is above 40
Exclusion Criteria:
Fracture report during the study period; Unwillingness of participants to continue the project; The occurrence of any visible side effects of supplemental effects
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: postmenopausal osteopenic women receiveing Oligopin
postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
|
Oligopin ,150 mg ,once daily, 12 week
|
Placebo Comparator: postmenopausal osteopenic women receiving placebo
postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
|
Placebo,150 mg ,once daily, 12 week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Osteocalcin Concentration
Time Frame: up to third month after intervention
|
Osteocalcin levels in plasma
|
up to third month after intervention
|
Plasma Carboxyl terminal collagen type I Concentration
Time Frame: up to third month after intervention
|
Carboxyl terminal collagen type I in plasma
|
up to third month after intervention
|
Osteocalcin/Carboxyl terminal collagen type I ratio
Time Frame: up to third month after intervention
|
Osteocalcin/Carboxyl terminal collagen type I ratio
|
up to third month after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MnSOD activity in peripheral blood mononuclear cells
Time Frame: Baseline and third month after intervention
|
MnSOD activity in peripheral blood mononuclear cells
|
Baseline and third month after intervention
|
Catalase activity in peripheral blood mononuclear cells
Time Frame: Baseline and third month after intervention
|
Catalase activity in peripheral blood mono nuclear cells
|
Baseline and third month after intervention
|
MnSOD mRNA expression peripheral blood mononuclear cells
Time Frame: Baseline and third month after intervention
|
MnSOD mRNA expression peripheral blood mononuclear cells
|
Baseline and third month after intervention
|
Catalase mRNA expression peripheral blood mononuclear cells
Time Frame: Baseline and third month after intervention
|
Catalase mRNA expression peripheral blood mononuclear cells
|
Baseline and third month after intervention
|
NrF2 mRNA expression peripheral blood mononuclear cells
Time Frame: Baseline and third month after intervention
|
NrF2 mRNA expression peripheral blood mononuclear cells
|
Baseline and third month after intervention
|
Plasma Malondialdehide Concentration
Time Frame: Baseline and third month after intervention
|
Malondialdehide levels in plasma
|
Baseline and third month after intervention
|
total antioxidant capacity
Time Frame: Baseline and third month after intervention
|
total antioxidant capacity in plasma
|
Baseline and third month after intervention
|
protein carbonyl content
Time Frame: Baseline and third month after intervention
|
protein carbonyl content in plasma
|
Baseline and third month after intervention
|
Plasma Total thiol concentration
Time Frame: Baseline and third month after intervention
|
Total thiol level in plasma
|
Baseline and third month after intervention
|
Catalase activity in Plasma
Time Frame: Baseline and third month after intervention
|
Catalase activity in plasma
|
Baseline and third month after intervention
|
MnSOD activity in Plasma
Time Frame: Baseline and third month after intervention
|
MnSOD activity in plasma
|
Baseline and third month after intervention
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 34606
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteopenia
-
Naturex SAAtlantia Food Clinical TrialsCompletedOsteopenia, GeneralizedIreland
-
Instituto de Investigación Hospital Universitario...Completed
-
National and Kapodistrian University of AthensNational Hellenic Research FoundationCompletedOsteopenia | Postmenopausal OsteopeniaGreece
-
Chinese PLA General HospitalBeijing Jishuitan Hospital; Beijing Aerospace General HospitalUnknownOsteoporosis | Osteopenia, OsteoporosisChina
-
NestléInstitut National de la Recherche Agronomique; Centre de Recherche en Nutrition...CompletedOsteoporosis, OsteopeniaFrance
-
Ioannis K. Triantafyllopoulos, MD,MSci,PhDCompletedOsteopenia | Postmenopausal Osteopenia
-
MeddocThe Research Council of Norway; TineRecruitingOsteopenia or OsteoporosisNorway
-
Hofseth Biocare ASAMøre og Romsdal Hospital TrustActive, not recruitingOsteopenia | Osteopenia of the ElderlyNorway
-
Aarhus University HospitalCompleted
-
Umm Al-Qura UniversityCompletedOsteopenia or OsteoporosisSaudi Arabia
Clinical Trials on Oligopin
-
Technological Centre of Nutrition and Health, SpainUniversity Rovira i Virgili; Hospital Universitari Sant Joan de Reus; Fundació... and other collaboratorsCompleted
-
Taipei Medical UniversityCompleted
-
Mashhad University of Medical SciencesCompletedTraumatic Brain InjuryIran, Islamic Republic of
-
Les Derives Resiniques et TerpeniquesKGK Science Inc.Active, not recruiting
-
Technological Centre of Nutrition and Health, SpainCompleted
-
Mylan Pharmaceuticals IncCompleted